G1043

Guanfacine hydrochloride

≥98% (HPLC)

• Sinónimos: N (Aminoiminomethyl)-2,6-dichlorobenzeneacetamide
• Fórmula empírica (notación de Hill): C₉H₉Cl₂N₃O · HCl
• Número de CAS: 29110-48-3
• Peso molecular: 282.55
• MDL number: MFCD00798230
• UNSPSC Code: 12352200
• PubChem Substance ID: 24278452
• NACRES: NA.77

Propiedades

• Quality Level: 100
• assay: ≥98% (HPLC)
• color: white
• solubility: H₂O: soluble 12 mg/mL at 60 °C
• originator: Promius
• SMILES string: Cl.NC(=N)NC(=O)Cc1c(Cl)cccc1Cl
• InChI: 1S/C9H9Cl2N3O.ClH/c10-6-2-1-3-7(11)5(6)4-8(15)14-9(12)13;/h1-3H,4H2,(H4,12,13,14,15);1H
• InChI key: DGFYECXYGUIODH-UHFFFAOYSA-N
• Gene Information: human ... ADRA2A(150) , ADRA2B(151) , ADRA2C(152)

Descripción

Application

Guanfacine hydrochloride has been used as an α2A adrenoceptor agonist to test its protective effect on hypobaric hypoxia (HH) and in rat brain to measure blood oxygenation level dependent (BOLD) response.

Biochem/physiol Actions

Guanfacine stimulates the brain postsynaptic α2 adrenergic receptor (AR) and mediates the prefrontal cortical (PFC) neuronal regulation and strengthens their network. Guanfacine improves the density of neuronal dendrites and is useful in treating neuropsychiatric disorders. It modulates the synaptic and cytoskeletal proteins expression in prefrontal cortical (PFC) neurons and may improve hypobaric hypoxia (HH) induced PFC dysfunctions. Guanfacine enhances cognitive function and is recommended for attention deficit hyperactivity disorder (ADHD) therapy.

α-2 noradrenergic receptor agonist.

Features and Benefits

This compound was developed by Promius. To browse the list of other pharma-developed compounds and Approved Drugs/Drug Candidates, click here.

Información de seguridad

• Storage Class: 11 - Combustible Solids
• wgk_germany: WGK 3
• flash_point_f: Not applicable
• flash_point_c: Not applicable
• ppe: Eyeshields, Gloves, type N95 (US)